{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:56:41Z","timestamp":1776675401206,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianshan Talent Project","award":["2022D01C632"],"award-info":[{"award-number":["2022D01C632"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04712-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:32:28Z","timestamp":1773289948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and biochemical factors associated with moderate-to-severe ulcerative colitis: a retrospective case\u2013control study"],"prefix":"10.1186","volume":"26","author":[{"given":"Chenfei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"4712_CR1","unstructured":"Chong H. Clinical study on vedolizumab combined with sulfasalazine in treatment of moderate to severe ulcerative colitis. Drugs Clin. 2024."},{"issue":"5","key":"4712_CR2","doi-asserted-by":"publisher","first-page":"e882","DOI":"10.1002\/hsr2.882","volume":"7","author":"KR Motawea","year":"2024","unstructured":"Motawea KR, Elsayed SM, Elhalag RH, et al. Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta-analysis. Health Sci Rep. 2024;7(5):e882.","journal-title":"Health Sci Rep"},{"issue":"1","key":"4712_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40885-023-00245-6","volume":"29","author":"A Elahi","year":"2023","unstructured":"Elahi A, Ali AA, Ahsan Choudhary A, et al. Challenges of managing hypertension in Pakistan - a review. Clin Hypertens. 2023;29(1):17.","journal-title":"Clin Hypertens"},{"issue":"1","key":"4712_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ueg2.12351","volume":"11","author":"J He","year":"2023","unstructured":"He J, Liu Z, Chen H, et al. Ulcerative colitis increases risk of hypertension in a UK biobank cohort study. United Eur Gastroenterol J. 2023;11(1):19\u201330.","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"4712_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/jcm11020400","volume":"11","author":"A Kaluzna","year":"2022","unstructured":"Kaluzna A, Olczyk P, Komosinska-Vassev K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J Clin Med. 2022;11(2):400.","journal-title":"J Clin Med"},{"issue":"5","key":"4712_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.17116\/patol20198105153","volume":"81","author":"EA Postovalova","year":"2019","unstructured":"Postovalova EA, Makarova OV, Kosyreva AM, et al. Morphology of the thymus and the specific features of its cellular composition in experimental acute and chronic ulcerative colitis. Arkh Patol. 2019;81(5):53\u201363.","journal-title":"Arkh Patol"},{"issue":"1","key":"4712_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1875318302111010008","volume":"11","author":"S El Sharawy","year":"2021","unstructured":"El Sharawy S, El-Horany H, Amer I. Corrected ESR\/albumin ratio as a simple, practical marker predicts the severity in Egyptian ulcerative colitis patients. Open Biomark J. 2021;11(1):8\u201316.","journal-title":"Open Biomark J"},{"issue":"09","key":"4712_CR8","first-page":"796","volume":"38","author":"K Wu","year":"2018","unstructured":"Wu K, Liang J, Ran Z, et al. Consensus on the diagnosis and treatment of inflammatory bowel disease (2018, Beijing). Chin J Pract Intern Med. 2018;38(09):796\u2013813.","journal-title":"Chin J Pract Intern Med"},{"issue":"4947","key":"4712_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;2(4947):1041\u20138.","journal-title":"BMJ"},{"issue":"13","key":"4712_CR10","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.3390\/ijerph18137159","volume":"18","author":"C Calvi\u00f1o-Su\u00e1rez","year":"2021","unstructured":"Calvi\u00f1o-Su\u00e1rez C, Ferreiro-Iglesias R, Bast\u00f3n-Rey I, et al. Role of quality of life as endpoint for inflammatory bowel disease treatment. Int J Environ Res Public Health. 2021;18(13):7159.","journal-title":"Int J Environ Res Public Health"},{"issue":"25","key":"4712_CR11","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.3748\/wjg.v24.i25.2741","volume":"24","author":"J S\u00fdkora","year":"2018","unstructured":"S\u00fdkora J, Pomaha\u010dov\u00e1 R, Kreslov\u00e1 M, et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24(25):2741\u201363.","journal-title":"World J Gastroenterol"},{"issue":"10114","key":"4712_CR12","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u201378.","journal-title":"Lancet"},{"issue":"18","key":"4712_CR13","first-page":"2962","volume":"35","author":"Q He","year":"2019","unstructured":"He Q, Li J. Advances in epidemiological studies of inflammatory bowel disease. J Pract Med. 2019;35(18):2962\u20136.","journal-title":"J Pract Med"},{"issue":"5","key":"4712_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/jch.13269","volume":"20","author":"CB Triches","year":"2018","unstructured":"Triches CB, Mayer A, Hoppe L, et al. Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension. J Clin Hypertens (Greenwich). 2018;20(5):935\u201341.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"4712_CR15","first-page":"1756","volume":"17","author":"W Liu","year":"2019","unstructured":"Liu W, Liu Y, Yu Q, et al. Expression of Hcy and blood lipid levels in serum of CHD patients and analysis of risk factors for CHD. Exp Ther Med. 2019;17(3):1756\u201360.","journal-title":"Exp Ther Med"},{"issue":"8","key":"4712_CR16","first-page":"658","volume":"95","author":"GR Bicbavova","year":"2023","unstructured":"Bicbavova GR, Drapkina OM, Livzan MA, et al. Cardiovascular risk factors in patients with ulcerative colitis. Ter Arkh. 2023;95(8):658\u201363 Russian.","journal-title":"Ter Arkh"},{"key":"4712_CR17","first-page":"167","volume":"02","author":"Y Luan","year":"2008","unstructured":"Luan Y. Evaluation of the efficacy of the combination of erythrocyte sedimentation rate and C-reactive protein in patients with ulcerative colitis. Henan Med Res. 2008;02:167-8,174.","journal-title":"Henan Med Res"},{"issue":"9","key":"4712_CR18","first-page":"50","volume":"35","author":"J Chen","year":"2015","unstructured":"Chen J, Fang Q. Infliximab in the treatment of moderate to severe ulcerative colitis. J Clin Med. 2015;35(9):50\u20131.","journal-title":"J Clin Med"},{"issue":"9","key":"4712_CR19","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/ibd\/izaa309","volume":"27","author":"SH Lee","year":"2021","unstructured":"Lee SH, Kim MJ, Kim ES, et al. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. Inflamm Bowel Dis. 2021;27(9):1452\u201361.","journal-title":"Inflamm Bowel Dis"},{"key":"4712_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.redox.2015.06.008","volume":"5","author":"G Idelman","year":"2015","unstructured":"Idelman G, Smith DLH, Zucker SD. Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of NADPH oxidase. Redox Biol. 2015;5:398\u2013408.","journal-title":"Redox Biol"},{"key":"4712_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2018.10.028","volume":"488","author":"SC Chen","year":"2019","unstructured":"Chen SC, Lin CH, Hsu HC, et al. Serum bilirubin improves the risk predictions of cardiovascular and total death in diabetic patients. Clin Chim Acta. 2019;488:1\u20136.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"4712_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/ijms21020484","volume":"21","author":"S Shastri","year":"2020","unstructured":"Shastri S, Shinde T, Sohal SS, et al. Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms. Int J Mol Sci. 2020;21(2):484.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4712_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41563-019-0462-9","volume":"19","author":"Y Lee","year":"2020","unstructured":"Lee Y, Sugihara K, Gillilland MG 3rd, et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2020;19(1):118\u201326.","journal-title":"Nat Mater"},{"issue":"07","key":"4712_CR24","first-page":"603","volume":"39","author":"X Chen","year":"2024","unstructured":"Chen X, Huo L. The value of serum bilirubin and NBR in the assessment of ulcerative colitis. Clin Focus. 2024;39(07):603\u201311.","journal-title":"Clin Focus"},{"key":"4712_CR25","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3389\/fimmu.2020.01847","volume":"11","author":"B Creyns","year":"2020","unstructured":"Creyns B, Jacobs I, Verstockt B, et al. Biological therapy in inflammatory bowel disease patients partly restores intestinal innate lymphoid cell subtype equilibrium. Front Immunol. 2020;11:1847.","journal-title":"Front Immunol"},{"issue":"11","key":"4712_CR26","first-page":"1209","volume":"32","author":"Y Feng","year":"2023","unstructured":"Feng Y, Li X, Zhang H, et al. Connexin is involved in the inflammatory response in ulcerative colitis through T lymphocytes. J Gastroenterol Hepatol. 2023;32(11):1209\u201313.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"4712_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"4712_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/00365521.2018.1447597","volume":"53","author":"B Ahluwalia","year":"2018","unstructured":"Ahluwalia B, Moraes L, Magnusson MK, et al. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018;53(4):379\u201389.","journal-title":"Scand J Gastroenterol"},{"issue":"27","key":"4712_CR29","first-page":"3178","volume":"17","author":"B Siegmund","year":"2011","unstructured":"Siegmund B, Zeitz M. Innate and adaptive immunity in inflammatory bowel disease. World J Gastroenterol. 2011;17(27):3178\u201383.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"4712_CR30","first-page":"1357","volume":"34","author":"YJ Chen","year":"2023","unstructured":"Chen YJ. Research progress on biologic therapy and surgical treatment for moderate to severe ulcerative colitis. Hainan Med J. 2023;34(9):1357\u201360.","journal-title":"Hainan Med J"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04712-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04712-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04712-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:19:29Z","timestamp":1776673169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04712-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4712"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04712-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that all experiments were performed in accordance with the Declaration of Helsinki. The study was approved by the Ethical Committee of the People's Hospital of Xinjiang Uygur Autonomous Region, NO. KY2024052414. Each patient provided written informed consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}